Contents

SynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyDrug Reaction DataReferences

View all Images (49)

Lymphomatoid papulosis in Adult
Other Resources UpToDate PubMed

Lymphomatoid papulosis in Adult

Contributors: Vincent Hensperger, Amy Kalowitz Bieber MD, Belinda Tan MD, PhD, Susan Burgin MD
Other Resources UpToDate PubMed

Synopsis

Lymphomatoid papulosis (LyP) is a recurrent, chronic, self-healing eruption that exists on a continuum with primary cutaneous anaplastic large cell lymphoma (C-ALCL). These 2 entities and their overlap cases make up the CD30-positive cutaneous lymphoproliferative disorders that represent about 25% of cutaneous T-cell lymphomas. Despite its malignant histopathologic qualities, LyP generally follows a benign clinical course. LyP and C-ALCL share many histopathologic features; morphology and disease course are important distinguishing factors.

LyP has an incidence of roughly 1.2-1.9 cases per 1 000 000 people and may occur at any age, although it is unusual in childhood. LyP is characterized by recurrent crops of pruritic, papulonecrotic, or nodular lesions that are self-healing over weeks or months. Lesions in various stages of healing are often seen. Lesions are often pruritic and may resolve with scarring. Six histopathologic subtypes are recognized by the 2018 World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification and are described in Best Tests. Specific subtypes of LyP do not correlate with clinical findings. Both the clinical history and histopathologic findings must be consistent with LyP for diagnosis; histopathology alone is not sufficient.

The cause of LyP is unknown, and its pathogenesis is only partially understood. Interactions between CD30 and its ligand appear to be important, and mutations in TGF-beta receptors may contribute. Identification of human T-cell lymphotropic virus type 1 (HTLV-1), herpesviruses 6, 7, and 8, and human endogenous retroviruses within LyP has been reported, but no clear relationship has been found. Several reports also suggest radiation therapy and fingolimod as triggers.

There is debate whether LyP is an inflammatory disorder or an indolent T-cell malignancy, but most authors categorize it as the latter. Most patients with LyP have chronic, self-limited eruptions. It is estimated that 15%-50% of patients with LyP will develop another lymphoproliferative disorder, such as ALCL, Hodgkin disease, or mycosis fungoides (MF). Patients with LyP should be monitored closely for these additional malignancies. A cohort study comprised of 504 LyP patients found that there was an increased risk of developing nonhematologic malignancies such as squamous cell carcinoma (SCC), melanoma, bladder cancer, and lung cancer. Further data confirming these findings are needed.

LyP has a 10-year disease-specific survival rate of close to 100%.

Codes

ICD10CM:
C86.6 – Primary cutaneous CD30-positive T-cell proliferations

SNOMEDCT:
31047003 – Lymphomatoid papulosis

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

To perform a comparison, select diagnoses from the classic differential

Subscription Required

Best Tests

Subscription Required

Management Pearls

Subscription Required

Therapy

Subscription Required

Drug Reaction Data

Subscription Required

References

Subscription Required

Last Reviewed:08/07/2022
Last Updated:08/08/2022
Copyright © 2024 VisualDx®. All rights reserved.
Lymphomatoid papulosis in Adult
A medical illustration showing key findings of Lymphomatoid papulosis : Scattered many
Clinical image of Lymphomatoid papulosis - imageId=68620. Click to open in gallery.  caption: 'Numerous erythematous papules and some nodules, one with a central crusted ulcer, on the arm.'
Numerous erythematous papules and some nodules, one with a central crusted ulcer, on the arm.
Copyright © 2024 VisualDx®. All rights reserved.